AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03504241
Drug: mycophenolate acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per protocol, and, only permitted in cases of sirolimus intolerance.
Trial: NCT03662659
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin + capecitabine
Trial: NCT00740324
Drug: NPO-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPO-11 after administration of NPO-11
Trial: NCT00740324
Drug: NPO-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glucagons after administration of NPO-11
Trial: NCT04152551
Drug: Risedronate Oral Tablet
RxNorm normalized name: risedronate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisphosphonate
Trial: NCT01958021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
Trial: NCT04576689
Drug: IBE-814 70ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least 10 and up to 33 participants will receive one (1) IBE-814. Route of administration: intravitreal injection.
Trial: NCT04576689
Drug: IBE-814 140ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 27 participants will receive two (2) IBE-814. Route of administration: intravitreal injection.
Trial: NCT02798471
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
Trial: NCT01742078
Drug: LY2541546 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01742078
Drug: LY2541546 - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01742078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV or SC
Trial: NCT00630487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
Trial: NCT00224432
Drug: probiotics: Lactobacillus GG, lactobacillus Rhamnosus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02422615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
Trial: NCT00990808
Drug: Comparator: placebo to MK0859
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to MK0859 once daily for 4 weeks.
Trial: NCT02034292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01739244
Drug: SYL040012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular topical administration of SYL040012 for 14 consecutive days
Trial: NCT01739244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular topical administration of placebo for 14 consecutive days
Trial: NCT04029909
Drug: 0.8mg/m2/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
Trial: NCT04029909
Drug: 0.4mg/m2/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
Trial: NCT04657172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ophthalmic solution administered with the Optejet microdose dispenser
Trial: NCT00739908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six capsules administered three times a day for six weeks.
Trial: NCT00003867
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01440933
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
Trial: NCT02972788
Drug: Enamel Matrix Proteins Derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
Trial: NCT02020694
Drug: Placebo (for vitamin D)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.
Trial: NCT02576275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
Trial: NCT01231438
Drug: Etalpha
RxNorm normalized name: Zenalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25ug o.d. for 2 weeks
Trial: NCT02095717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00404742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO BID
Trial: NCT00979121
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
Trial: NCT00979121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
Trial: NCT01009177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00872729
Drug: Cystagon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H.
Trial: NCT00872729
Drug: RP103
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.
Trial: NCT02843191
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
Trial: NCT02211768
Drug: [18F]-FLT-PET/CT scans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
Trial: NCT03610971
Drug: BCR-ABL Tyrosine Kinase Inhibitor (TKI)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
Trial: NCT03817398
Drug: Tyrosine Kinase Inhibitor
RxNorm normalized name: Protein-tyrosine kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-start TKI medication
Trial: NCT04499859
Drug: Ezetimibe 10mg + Rosuvastatin 5mg
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
Trial: NCT04499859
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg of Rosuvastatin as a standard treatment for AMI patients
Trial: NCT00840047
Drug: Methionine
RxNorm normalized name: Methionine
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT00604890
Drug: API 31510 3% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment 3% active cream applied to the lesion
Trial: NCT00604890
Drug: API 31510 1.5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment 1.5% active cream applied to the lesion
Trial: NCT03532139
Drug: Enoxaparin + Rosuvastatin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
Trial: NCT00664209
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo therapy
Trial: NCT03616886
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Trial: NCT03616886
Drug: MEDI9447
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Trial: NCT00804375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cutaneous solution to be applied twice daily for 84 days
Trial: NCT01953900
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
Trial: NCT02609789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 percent (%) normal saline.
Trial: NCT03508700
Drug: TNX-102 SL 5.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclobenzaprine HCl sublingual tablets
Trial: NCT04353778
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo x 8 weeks
Trial: NCT03411421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be administered.
Trial: NCT02564978
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
Trial: NCT03659136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00237016
Drug: doxycycline treatment
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04068103
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04068103
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04068103
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04068103
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03508232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
Trial: NCT03753555
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140mg subcutaneously injected, twice each month
Trial: NCT03419234
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
Trial: NCT03997786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Weeks 16 to 52)
Trial: NCT01614405
Drug: TDF/FTC/LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
Trial: NCT01614405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
Trial: NCT00968149
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo chewable tablet daily at bed time for 2 weeks
Trial: NCT02588443
Drug: RO70097890
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02962284
Drug: abiraterone acetate with Methylprednisolone
RxNorm normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
Trial: NCT02454283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01872494
Drug: flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01398267
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
Trial: NCT02795754
Drug: GSK2838232 IR1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 will be available as film-coated tablet for oral use
Trial: NCT02795754
Drug: GSK2838232 IR2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 will be available as film-coated tablet for oral use
Trial: NCT02795754
Drug: Placebo PIB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
Trial: NCT00557284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral granules or chewable tablet, PO QD (given oral daily)
Trial: NCT05036837
Drug: OZOPROMAF_SEQ1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ.
Trial: NCT04541797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
Trial: NCT02254720
Drug: BEA 2180 BR solution for infusion
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02254720
Drug: BEA 2180 BR solution for inhalation
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01574716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02438137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
Trial: NCT00111631
Drug: DPP-IV Inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses po bid
Trial: NCT00111631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po bid
Trial: NCT00448552
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02291913
Drug: Toremifine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-estrogen therapy
Trial: NCT02132949
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
Trial: NCT02132949
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
Trial: NCT03202992
Drug: ABI-1968
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
Trial: NCT02917512
Drug: HU00701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 0.01% + 3% trehalose
Trial: NCT02917512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT02056236
Drug: Anti-epileptic drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented.
Trial: NCT04316936
Drug: Dexycu, 9% Intraocular Suspension
RxNorm normalized name: Dexycu, 9% intraocular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone intraocular suspension
Trial: NCT04316936
Drug: Prednisolone Acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard postoperative ophthalmic drop regimen
Trial: NCT03035084
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT04593238
Drug: Double Antibiotic paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole and Ciprofloxacin